• Shire plc, of Dublin, Ireland, said it received approval through the European decentralized procedure for an oral powder formulation of Fosrenol (lanthanum carbonate), a noncalcium, nonresin phosphate binder, for use in the control of hyperphosphatemia in chronic renal failure patients on hemodialysis or continuous ambulatory peritoneal dialysis.